CliffBio
small molecule

VASOCIDIN

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameVASOCIDIN
Active ingredientPREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
Strength0.5%;10%
Dosage formOINTMENT
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 1984
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.